Situation and trends
Expanded access to antiretroviral therapy (ART) and a declining incidence of HIV infections have led to a steep fall globally in the number of adults and children dying from HIV-related causes. The estimated 770 000 [570 000−1 100 000] people dying from HIV globally in 2018 were 56% fewer than in 2004 (the peak) and 33% fewer than in 2010 in spite of a period of substantial population growth in many high burden countries.
Nevertheless, there is no room for complacency. Countries need to live up to their commitment to end the AIDS epidemic as a public health threat by 2030 -- a target included in the 2030 Agenda for Sustainable Development adopted by the United Nations General Assembly in September 2015. The immediate challenge is to reach the Fast-Track targets for 2020, as HIV-related deaths are still unacceptably high.
The 2020 targets include reducing the number of people dying from HIV-related causes to fewer than 500 000. Based on current estimates, this provides an opportunity to prevent almost 300 000 deaths per year.
The drop in HIV-related mortality is especially evident in the regions with the greatest burden of HIV infection, including the WHO African Region, home to over 61% of people dying from HIV-related causes in 2018. An estimated 470 000 [340 000−630 000] people died in the African Region from HIV-related causes in 2018, which indicates that mortality has dropped by almost 40% since 2010.
Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. Immunotech BG-Europe , under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS.
ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe.
Additionally, ImmunoTech BG-Europe has informed Enzolytics that they will be seeking to register the ImmunH product as a ImmuneModulator, allowing use as an adjunct in additional applications to regulate or normalize the Immune System.